Affinity-Based Drug Release Formulations for Retinal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for retinal drug delivery, such as intravitreal injections, are invasive and frequent, leading to systemic side effects, ocular complications, and limited drug selection due to poor drug distribution and short half-life of protein therapeutics, necessitating a more efficient and sustained release system.
Innovation Solution
A two-step physical interaction mechanism using affinity binding pairs like streptavidin-desthiobiotin, where a drug conjugate is immobilized in hydrogels and released by a competitive binding compound, allowing for controlled and sustained release of therapeutics like Avastin® (bevacizumab) by tuning the solubility of biotin derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravitreal injections are used for retinal drug delivery, then drug delivery efficiency is improved, but injection frequency must be high due to short half-life, leading to increased ocular complications and systemic side effects
Solution Approach 1:
The patent employs dynamic affinity interactions between streptavidin and biotin/desthiobiotin that can reversibly bind and release drugs. The system transitions from a bound state (drug immobilized on hydrogel) to a released state (drug freed by competitive binding), allowing controlled temporal delivery that extends drug half-life and reduces injection frequency while maintaining therapeutic efficacy
Solution Approach 2:
The patent introduces streptavidin-biotin affinity pairs as intermediary binding mechanisms between the hydrogel carrier and the therapeutic drug. This intermediary system enables controlled drug release through competitive binding, allowing the drug to be held in a reservoir and released on demand, thereby extending its effective half-life and reducing the need for frequent injections
2Reliability
If protein therapeutics are administered frequently to maintain efficacy, then drug effectiveness is improved, but patient compliance decreases and health care costs increase
Solution Approach 1:
The patent implements preliminary action by pre-loading the hydrogel with high concentrations of therapeutic drugs in a stable, bound state. The drugs are immobilized on the hydrogel matrix through streptavidin-biotin interactions, creating a reservoir that can sustain release over extended periods. This preliminary loading eliminates the need for frequent administration, improving patient compliance while maintaining therapeutic effectiveness
3Ease of operation
If simple delivery methods are used, then ease of administration is improved, but drug distribution is poor and only 5% of topically applied drug enters the eye
Solution Approach 1:
The patent uses streptavidin-biotin affinity pairs as intermediaries to enhance drug delivery to the retina. The hydrogel system with immobilized streptavidin acts as a mediator that facilitates efficient drug transfer across the blood-retinal barrier, significantly improving drug distribution and penetration compared to simple topical application methods
4Reliability
If hydrogels are used for intravitreal drug delivery, then biocompatibility is improved, but injection frequency only marginally decreases to every 2-3 months
Solution Approach 1:
The patent applies parameter changes by modifying the affinity binding characteristics of the hydrogel system. By using streptavidin with high affinity for biotin and desthiobiotin, and by controlling the concentration and solubility of these binding partners in the hydrogel, the system achieves extended drug release durations that go beyond the conventional 2-3 month interval, further reducing injection frequency while maintaining biocompatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system achieves a highly controlled and sustained release of drugs over several months to a year, reducing injection frequency, minimizing side effects, and maintaining drug efficacy, suitable for both injectable and implantable hydrogels.
Implementation Method 1
affinity binding pairs like streptavidin-desthiobiotin, where a drug conjugate is immobilized in hydrogels
Implementation Method 2
Affinity is often used to describe the favourable noncovalent interaction between two macromolecules
Implementation Method 3
a competitive binding compound that disrupts the binding between the drug conjugate and the second member of the affinity binding pair
Implementation Method 4
release is dictated by the binding and unbinding kinetics as well as Fickian diffusion kinetics
Data Source
AI summary
The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.